Piramal Pharma Share Price Outlook: Where Could It Be by 2030?

Piramal Pharma share price Rs 174 (10 July 2026). 52W high Rs 221, low Rs 132. Market cap Rs 23,099 Cr. 2030 scenario range Rs 190 to Rs 315.

The Piramal Pharma share price forecast for the next 3 years is a question on many investors’ minds as the stock trades at Rs 174 on 10 July 2026, within a 52 week range of Rs 132 to Rs 221. This article lays out a scenario based Piramal Pharma share price outlook for 2027, 2028 and 2030, built on the company’s fundamentals, sector trends and the key risks that could change the trajectory. Rather than a single number, the focus here is on the range of outcomes and the assumptions behind each one.

Click Here – Get Free Investment Predictions

Piramal Pharma Company Overview

Piramal Pharma is a diversified pharma company with a global CDMO business, a branded consumer healthcare portfolio in India and a complex hospital generics business serving international markets. Understanding the business model is the first step in framing any credible Piramal Pharma share price forecast, because the durability of earnings ultimately decides where the stock trades.

Where Does Piramal Pharma Share Price Stand Today?

The stock currently trades about 21 percent below its 52 week high of Rs 221, which means the market has already tempered some of its optimism. For anyone building a Piramal Pharma share price forecast, this correction matters for the Piramal Pharma share price forecast starting point, because entry valuations have a large bearing on 3 year returns.

At the current price, Piramal Pharma commands a market capitalisation of Rs 23,099 Cr and trades at a price to earnings multiple of NA. The company generates a return on equity of 3.83% and a return on capital employed of 2.52%, which places it in the category of businesses with a recovering profitability profile. These numbers anchor the Piramal Pharma share price forecast scenarios that follow. How the broader Nifty 50 index trades over this period will also influence the multiple investors are willing to assign to the stock.

Piramal Pharma Share Price Forecast: Key Growth Drivers for the Next 3 Years

Four forces are likely to shape the Piramal Pharma share price forecast between now and 2030, and together they explain most of the dispersion in this Piramal Pharma share price forecast. Each is discussed below with its likely direction of impact.

Earnings Trajectory and Return Ratios

Stock prices ultimately follow earnings. With a recovering profitability profile at present, the pace at which profits compound over FY27 to FY30 will be the single biggest determinant of the Piramal Pharma share price forecast actually playing out. Consistent earnings delivery tends to expand valuation multiples, while misses compress them quickly.

Structural Tailwinds in Indian Pharmaceuticals

The Indian pharmaceutical market continues to grow in high single to low double digits, supported by chronic disease prevalence, better diagnosis rates and premiumisation of therapies. Companies with strong brand equity and field force productivity, like Piramal Pharma, are positioned to grow ahead of the market. Sector trends are visible in the Nifty Pharma index, which serves as a useful barometer for the space.

Within the space, investors often benchmark Piramal Pharma against peers such as Divis Laboratories, Laurus Labs and Sai Life Sciences on growth and valuations before forming a view on the Piramal Pharma share price forecast.

Company Specific Catalysts

The bull case for Piramal Pharma rests on CDMO capacity expansion, consumer healthcare brand growth in India and margin improvement across segments. If these play out on schedule, the Piramal Pharma share price forecast for 2030 could gravitate toward the upper end of the scenario range discussed below.

Macro Environment and Liquidity

The RBI rate cycle, FII flows into Indian equities and overall market valuations will influence the multiple investors are willing to pay. A benign macro backdrop supports the optimistic end of any Piramal Pharma share price forecast, while global risk aversion would do the opposite to the Piramal Pharma share price outlook.

Piramal Pharma Share Price Forecast 2027, 2028 and 2030: Scenario Analysis

The table below presents a scenario based Piramal Pharma share price forecast using compounded annual growth assumptions applied to the current market price of Rs 174. These are illustrative ranges, not point predictions, and actual outcomes can fall outside them.

In the base case scenario of this Piramal Pharma share price forecast, the 2030 level works out to roughly Rs 245, implying steady compounding from today’s levels. The bull case of Rs 315 assumes CDMO capacity expansion delivers ahead of expectations, while the bear case of Rs 190 captures a scenario where growth stalls. That is an outcome band of about 9 percent to 81 percent over the period.

Consult a SEBI Registered Investment Advisor Before Acting on Any Forecast

Bull Case vs Bear Case for Piramal Pharma Share Price

The Bull Case

The optimistic Piramal Pharma share price forecast assumes CDMO capacity expansion, consumer healthcare brand growth in India and margin improvement across segments. Combined with supportive sector conditions, this could lift both earnings and the valuation multiple, pushing the stock toward Rs 315 by 2030.

The Bear Case

The cautious view centres on the fact that global CDMO demand cycles and integration of multiple business lines under one entity are risks. If these pressures dominate, the Piramal Pharma share price forecast would skew toward the lower band and the stock could stagnate near Rs 190 even by 2030, underperforming broader indices.

Key Risks That Could Change the Piramal Pharma Share Price Outlook

• Execution risk: Delays in strategy execution or capacity plans would push the earnings trajectory below the base case assumed in this Piramal Pharma share price forecast.
• Valuation risk: At a PE of NA, any earnings disappointment can trigger sharp multiple compression before fundamentals stabilise.
• Sector risk: Global CDMO demand cycles and integration of multiple business lines under one entity are risks.
• Macro risk: A global slowdown, adverse FII flows or unexpected rate moves would compress equity valuations across the market.
• Regulatory risk: Policy, tax or compliance changes affecting the sector can alter the earnings outlook with little warning.

Is Piramal Pharma Worth Watching for the Long Term?

For long term investors, the relevant question is not just where the Piramal Pharma share price forecast lands in 2030 or what any single Piramal Pharma share price forecast says today, but whether the business can compound capital through cycles. The company’s positioning around CDMO capacity expansion gives it a credible growth story, while the risks outlined above define what must be monitored each quarter.

Investors should track quarterly earnings, management commentary and sector data rather than anchoring to any single number from a Piramal Pharma share price outlook. Historically, staying focused on business fundamentals has served investors better than chasing price targets, and consulting a SEBI registered advisor before investing remains the prudent approach.

Download the Univest iOS App or Univest Android App to track Piramal Pharma share price live.

Conclusion

The Piramal Pharma share price forecast for the next 3 years spans Rs 190 to Rs 315 by 2030 under the scenarios discussed, with a base case near Rs 245. Any credible Piramal Pharma share price forecast must be updated as facts change, and the path will be decided by earnings delivery, CDMO capacity expansion and the broader market environment. Treat these ranges as a framework for thinking, not a promise of outcomes, and revisit the assumptions as new results come in. Consult a SEBI registered investment advisor before making any investment decision.

What is the Piramal Pharma share price forecast for the next 3 years?

Ans. The Piramal Pharma share price forecast for the next 3 years is scenario based rather than a single number. By 2030, the illustrative range spans Rs 190 in the bear case to Rs 315 in the bull case, with a base case near Rs 245, depending on earnings delivery and market conditions.

What is the Piramal Pharma share price forecast for 2027?

Ans. For 2027, the scenario range works out to Rs 180 to Rs 210, with a base case around Rs 195. This assumes compounding on the current price of Rs 174 and is illustrative, not a guaranteed outcome.

What is the Piramal Pharma share price forecast for 2028?

Ans. The 2028 scenario range is Rs 185 to Rs 240, with the base case near Rs 210. Actual levels will depend on earnings growth, sector trends and overall market valuations at the time.

What is the current share price of Piramal Pharma?

Ans. As of 10 July 2026, Piramal Pharma trades at around Rs 174 on the NSE, within a 52 week range of Rs 132 to Rs 221. Prices change continuously during market hours, so check live quotes before acting.

Is Piramal Pharma a good stock for the long term?

Ans. Piramal Pharma has a credible long term story built on CDMO capacity expansion, but it also carries risks since global CDMO demand cycles and integration of multiple business lines under one entity are risks. Long term suitability depends on your risk profile and portfolio, so consult a SEBI registered investment advisor before investing.

What is the Piramal Pharma share price outlook for 2030?

Ans. The Piramal Pharma share price outlook for 2030 spans Rs 190 to Rs 315 across bear and bull scenarios. Where the stock actually lands will be driven by profit growth, valuation multiples and macro conditions closer to that date.

What are the key risks to the Piramal Pharma share price forecast?

Ans. The main risks are execution delays, valuation compression from the current PE of NA, sector specific pressures, macro shocks and regulatory changes. Any of these can push the stock below the base case scenario discussed in this article.